Liquidia Corporation LQDA L606 — Program Expenses

Similar metrics at other companies

ARVNOther programs — Program-specific external expense

$2.6M+52.9%

NUV

NUVLDiscovery Programs — Direct Expenses Related To Program

$2.8M+31.4%

PRAXRelutrigine — Program-specific expenses

$13.98M+33.0%

PRAXUlixacaltamide — Program-specific expenses

$13.3M-27.7%

PRAXVormatrigine — Program-specific expenses

$12.88M-28.3%

PRAXElsunersen — Program-specific expenses

$8.14M+518%

FAQ

What is Liquidia Corporation's l606 — program expenses?

Liquidia Corporation (LQDA) reported l606 — program expenses of $5.82M in Q1 2026.

How has Liquidia Corporation's l606 — program expenses changed year-over-year?

Liquidia Corporation's l606 — program expenses increased by 78.2% year-over-year, from $3.27M to $5.82M.

What is the long-term trend for Liquidia Corporation's l606 — program expenses?

Over 2 years (2023 to 2025), Liquidia Corporation's l606 — program expenses has grown at a 25.2% compound annual growth rate (CAGR), from $12.55M to $19.68M.

What does l606 — program expenses mean?

This metric represents the direct research, development, and clinical trial costs specifically allocated to a single pharmaceutical product candidate or therapeutic program. It captures the capital intensity required to advance a specific drug through regulatory milestones and commercial readiness. Monitoring these expenses helps investors assess the company's investment commitment to its core pipeline assets.